Gao, Qiang <br/><br/>
Infliximab treatment influences the serological expression of matrix metalloproteinase (MMP)-2 and -9 in Crohn's disease.  [electronic resource] 

 -  Inflammatory bowel diseases  Jun 2007 
 - 693-702 p.  digital 
<br/><br/> Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1078-0998 
<br/><br/><label>Standard No.: </label>10.1002/ibd.20100  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Aged<br/>Anti-Inflammatory Agents--therapeutic use<br/>Antibodies, Monoclonal--therapeutic use<br/>Biomarkers--blood<br/>Crohn Disease--blood<br/>Enzyme-Linked Immunosorbent Assay<br/>Follow-Up Studies<br/>Gene Expression--drug effects<br/>Humans<br/>Immunohistochemistry<br/>Infliximab<br/>Matrix Metalloproteinase 2--blood<br/>Matrix Metalloproteinase 9--blood<br/>Middle Aged<br/>Neutrophils--enzymology<br/>RNA, Messenger--genetics<br/>Reverse Transcriptase Polymerase Chain Reaction<br/>Treatment Outcome